We are live on
!
Find out more
RM
RP Management Portfolio holdings
AUM
$139M
1-Year Est. Return
37.98%
This Fund
S&P 500
This Quarter
Est. Return
-18.89%
1 Year Est. Return
-37.98%
3 Year Est. Return
+207.8%
5 Year Est. Return
+1,098.05%
10 Year Est. Return
–
AUM
$228M
AUM Growth
$0
(0%)
Cap. Flow
$0
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
–
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$2.43B
| $147M | 64.43% |
2,936,507
| – | – |
|
2
Cytokinetics
CYTK
$10.8B
| $51.8M | 22.73% |
980,392
| – | – |
|
3
BioCryst Pharmaceuticals
BCRX
$2.52B
| $29.2M | 12.84% |
3,846,154
| – | – |
|
|
VIRX
4
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $851 | ﹤0.01% |
3,700
| – | – |
|
Similar funds
PC
LA
TP
SC
MADFP
RM
NC
GWA
RP Management's Q4 2024 Portfolio in Review
As of Q4 2024, RP Management held 4 positions worth $228M, unchanged from the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q4 2024: portfolio turnover was 0%. RP Management opened no new positions and made no exits, leaving the 4-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- RP Management's ten largest holdings make up 100% of its $228M portfolio in Q4 2024.
- RP Management opened 0 new positions and closed 0 in Q4 2024.
- RP Management's portfolio value was unchanged quarter-over-quarter at $228M.
Based on RP Management's 13F filing for Q4 2024, filed 3 Feb 2025.